46258 Federal Register / Vol. 86, No. 157 / Wednesday, August 18, 2021 / Notices 

to plan, implement, and evaluate 

vaccination programs for influenza and 

COVID–19. 

Amount of Award: $47,000,000 in 

Federal Fiscal Year (FFY) 2021 funds, 

and an estimated total of $100,000,000 

over the five-year period of 

performance, subject to availability of 

funds. 

Period of Performance: September 30, 

2021 through September 29, 2026. 

Authority: Section 307 of the Public 

Health Service Act, as amended (42 

U.S.C. 242l). 

Dated: August 12, 2021. 

Joseph I. Hungate III, 

Deputy Director, Office of Financial 

Resources, Office of the Chief Operating 

Officer, Centers for Disease Control and 

Prevention. 

[FR Doc. 2021–17678 Filed 8–17–21; 8:45 am] 

BILLING CODE 4163–18–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Administration for Children and 

Families 

Notice of Meeting 

AGENCY: Office on Trafficking in 

Persons, Administration for Children 

and Families, Department of Health and 

Human Services. 

ACTION: Announcement of meeting and 

call for public comments on states’ 

efforts to improve the nation’s response 

to the sex trafficking of children and 

youth. 

SUMMARY: Notice is hereby given, 

pursuant to the provisions of the 

Federal Advisory Committee Act 

(FACA) and the Preventing Sex 

Trafficking and Strengthening Families 

Act, that a meeting of the National 

Advisory Committee on the Sex 

Trafficking of Children and Youth in the 

United States (the Committee) will be 

held on September 8 and 9, 2021. The 

purpose of the meeting is for the 

Committee to begin reviewing responses 

to the Committee’s State SelfAssessment Survey and develop a 

framework for the Committee’s final 

report. The members of the Committee 

request comments from the public to 

inform their ongoing work and final 

report. Please submit your comments to 

NAC@nhttac.org with the subject ‘‘NAC 

Comments’’ as soon as possible and 

before September 6, 2021. 

DATES: The meeting will be held on 

September 8 and 9, 2021. 

ADDRESSES: The meeting will be held 

virtually. Please register for this event 

online: https://www.acf.hhs.gov/otip/ 

partnerships/national-advisorycommittee. 

FOR FURTHER INFORMATION, CONTACT: 

Katherine Chon (Designated Federal 

Officer) at EndTrafficking@acf.hhs.gov 

or (202) 205–5778, or 330 C Street SW, 

Washington, DC 20201. Additional 

information is available at https://

www.acf.hhs.gov/otip/partnerships/thenational-advisory-committee. 

SUPPLEMENTARY INFORMATION: The 

formation and operation on behalf of the 

Committee are governed by the 

provisions of Public Law 92–463, as 

amended (5 U.S.C. App. 2), which sets 

forth standards for the formation and 

use of federal advisory committees. 

Purpose of the Committee: The 

purpose of the Committee is to advise 

the Secretary and the Attorney General 

on practical and general policies 

concerning improvements to the 

nation’s response to the sex trafficking 

of children and youth in the United 

States. HHS established the Committee 

pursuant to Section 121 of the 

Preventing Sex Trafficking and 

Strengthening Families Act of 2014 

(Pub. L. 113–183). 

Tentative Agenda: The agenda can be 

found at https://www.acf.hhs.gov/otip/ 

partnerships/the-national-advisorycommittee. To submit written 

statements, email NAC@nhttac.org, by 

September 6, 2021. Please include your 

name, organization, and phone number. 

More details on these options are below. 

Public Accessibility to the Meeting: 

Pursuant to 5 U.S.C. 552b and 41 CFR 

102–3.140 through 102–3.165, and 

subject to the availability of space, this 

meeting is open to the public virtually. 

Written Statements: Pursuant to 41 

CFR 102–3.105(j) and 102–3.140 and 

section 10(a)(3) of the Federal Advisory 

Committee Act, the public may submit 

written statements in response to the 

stated agenda of the meeting, or to the 

Committee’s mission, in general. 

Organizations with recommendations 

on strategies to engage states and 

stakeholders are encouraged to submit 

their comments or resources (hyperlinks 

preferred). Written comments or 

statements received after September 6, 

2021, may not be provided to the 

Committee until its next meeting. 

Verbal Statements: Pursuant to 41 

CFR 102–3.140d, the Committee is not 

obligated to allow a member of the 

public to speak or otherwise address the 

Committee during the meeting. 

Members of the public are invited to 

provide verbal statements during the 

Committee meeting only at the time and 

manner described in the agenda. The 

request to speak should include a brief 

statement of the subject matter to be 

addressed and should be relevant to the 

stated agenda of the meeting or the 

Committee’s mission in general. 

Minutes: The minutes of this meeting 

will be available for public review and 

copying within 90 days at: https://

www.acf.hhs.gov/otip/partnerships/thenational-advisory-committee. 

Linda Hitt, 

Director, Executive Secretariat. 

[FR Doc. 2021–17714 Filed 8–17–21; 8:45 am] 

BILLING CODE 4184–40–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: 

Elizabeth Pitts, Ph.D., 240–669–5299; 

elizabeth.pitts@nih.gov. Licensing 

information may be obtained by 

communicating with the indicated 

licensing contact at the Technology 

Transfer and Intellectual Property 

Office, National Institute of Allergy and 

Infectious Diseases, 5601 Fishers Lane, 

Rockville, MD 20852; tel. 301–496– 

2644. A signed Confidential Disclosure 

Agreement will be required to receive 

copies of unpublished information 

related to the invention. 

SUPPLEMENTARY INFORMATION: 

Technology description follows. 

Tumor Associated Calcium Signal 

Transducer 2 (TACSTD2)- 

Overexpressing Huh7.5 Cells That Are 

More Permissive to HCV Cell Entry and 

Replication Compared to the Model 

Huh7.5 Cell Line 

Description of Technology 

Worldwide, 130–150 million 

individuals are chronically infected 

with hepatitis C virus (HCV), a major 

cause of liver-associated morbidity and 

mortality worldwide. Despite recent 

advances in antiviral drugs that can cure 

some individuals, a rapid decline of the 


jbell on DSKJLSW7X2PROD with NOTICES
Federal Register / Vol. 86, No. 157 / Wednesday, August 18, 2021 / Notices 46259 

global disease burden is hampered by 

remarkably high treatment costs and a 

high number of undiagnosed infections. 

Moreover, a significant number of 

patients develop resistance and 

additional treatment modalities may be 

needed to dramatically reduce the 

worldwide incidence of HCV infection. 

The subject cell line may be a useful 

tool for studying the mechanism of HCV 

cellular entry and replication and could 

be incorporated into an in vitro assay to 

measure the effectiveness of novel HCV 

targeted therapies or as a system for 

improved propagation of HCV in 

culture. 

By overexpressing TACSTD2 in 

Huh7.5 cells, scientists at the National 

Institute of Allergy and Infectious 

Diseases (NIAID) discovered that they 

could restore the cellular localization of 

two host cell HCV-entry factors that 

become dysregulated in hepatocellular 

carcinoma (HCC) cells. Overexpression 

of TACSTD2 makes Huh7.5 cells more 

broadly permissive to infection and 

replication by multiple HCV genotypes 

in comparison to the canonical Huh7.5 

cell model. HCV does not replicate in 

malignant HCC cells, possibly caused in 

part by downregulation of TACSTD2 

expression. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404. 

Potential Commercial Applications 

• Cell line to study hepatitis C virus

infection and replication or propagate 

HCV in culture. 

• Cell line to study cancer.

Development Stage 

• Material.

Inventors: Patrizia Farci and Vandana

Sekhar (NIAID). 

Publication: Sekhar V, Pollicino T, 

Diaz G, Engle RE, Alayli F, Melis M, 

Kabat J, Tice A, Pomerenke A, AltanBonnet N, Zamboni F, Lusso P, Emerson 

SU, and Farci P. (2018) Infection with 

hepatitis C virus depends on TACSTD2, 

a regulator of claudin-1 and occludin 

highly downregulated in hepatocellular 

carcinoma. PLoS Pathog 14: e1006916. 

doi: 10.1371/journal.ppat.1006916. 

Licensing Contact: To license this 

technology, please contact Elizabeth 

Pitts, Ph.D., 240–669–5299; 

elizabeth.pitts@nih.gov, and reference 

E–040–2020. 

Dated: August 12, 2021. 

Surekha Vathyam, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2021–17687 Filed 8–17–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Cancer Institute; Notice of 

Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Cancer 

Advisory Board. 

The meeting will be held as a virtual 

meeting and is open to the public as 

indicated below. Individuals who plan 

to view the virtual meeting and need 

special assistance or other reasonable 

accommodations to view the meeting 

should notify the Contact Person listed 

below in advance of the meeting. The 

meeting will be videocast and can be 

accessed from the NIH Videocasting and 

Podcasting website (http://

videocast.nih.gov/). 

A portion of the National Cancer 

Advisory Board meeting will be closed 

to the public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Cancer 

Advisory Board. 

Date: August 31, 2021. 

Open: 1:00 p.m. to 3:10 p.m. 

Agenda: NCAB Subcommittee Meetings— 

Subcommittee on Planning and Budget and 

Ad Hoc Subcommittee on Global Cancer 

Research. 

Place: National Cancer Institute—Shady 

Grove, 9609 Medical Center Drive, Rockville, 

MD 20850 (Virtual Meeting). 

Name of Committee: National Cancer 

Advisory Board. 

Date: September 1, 2021. 

Open: 1:00 p.m. to 4:15 p.m. 

Agenda: Director’s and Program reports 

and presentations; business of the Board. 

Closed: 4:25 p.m. to 5:30 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Cancer Institute—Shady 

Grove, 9609 Medical Center Drive, Rockville, 

MD 20850 (Virtual Meeting). 

Contact Person: Paulette S. Gray, Ph.D., 

Director, Division of Extramural Activities, 

National Cancer Institute—Shady Grove, 

National Institutes of Health, 9609 Medical 

Center Drive, 7th Floor, Room 7W444, 

Bethesda, MD 20892, 240–276–6340, grayp@

mail.nih.gov. 

Any interested person may file written 

comments with the committee by forwarding 

the statement to the Contact Person listed on 

this notice. The statement should include the 

name, address, telephone number and when 

applicable, the business or professional 

affiliation of the interested person. 

Information is also available on the 

Institute’s/Center’s home page: NCAB: 

https://deainfo.nci.nih.gov/advisory/ncab/ 

ncabmeetings.htm, where an agenda and any 

additional information for the meetings will 

be posted when available. 

This notice is being published less than 15 

days prior to the meeting due to scheduling 

difficulties. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.392, Cancer Construction; 

93.393, Cancer Cause and Prevention 

Research; 93.394, Cancer Detection and 

Diagnosis Research; 93.395, Cancer 

Treatment Research; 93.396, Cancer Biology 

Research; 93.397, Cancer Centers Support; 

93.398, Cancer Research Manpower; 93.399, 

Cancer Control, National Institutes of Health, 

HHS) 

Dated: August 13, 2021. 

Melanie J. Pantoja, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2021–17742 Filed 8–17–21; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute of Nursing Research; 

Notice of Meeting 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of a 

meeting of the National Advisory 

Council for Nursing Research. 

The meeting will be open to the 

public as indicated below via videocast. 

The URL link to this meeting is https:// 

videocast.nih.gov/watch=42425. 

Individuals who plan to attend and 

need special assistance, such as sign 

language interpretation or other 

reasonable accommodations, should 

notify the Contact Person listed below 

in advance of the meeting. 

The meeting will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Advisory 

Council for Nursing Research. 

Date: September 14, 2021. 

Open: 11:00 a.m. to 3:30 p.m. 


jbell on DSKJLSW7X2PROD with NOTICES